Replies to post #145064 on Biotech Values

[DewDiligence]

Merck KGaA withdraws Erbitux MAA in NSCLC—again:

http://www.reuters.com/article/2012/09/18/us-merck-erbitux-idUSBRE88H09420120918

Merck said on Tuesday it gave up the new attempt it made in March to win EU approval for the use of its second best-selling drug Erbitux against lung cancer, which had targeted a quarter of the patients it had initially tried to address.

"The decision to withdraw the application was based on feedback from European regulatory authorities, indicating that further data would be required," Merck said in a statement.